Telo Therapeutics is developing orally bioavailable nuclear transport inhibitors, specifically TSM74, which targets XPO1 to degrade proteins involved in cancer cell signaling. This approach aims to treat cancers that are resistant to existing therapies, improving safety and efficacy by promoting rapid tumor regression in preclinical models.
Funding
$5.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to existing therapies due to dysregulation of nuclear transport, a process critical for cancer cell signaling. Current treatments targeting this mechanism often exhibit significant toxicity, limiting their clinical utility. This creates a need for safer and more effective therapies that can overcome resistance and improve patient outcomes.
Solution
Telo Therapeutics is developing orally bioavailable, next-generation nuclear transport inhibitors, with a focus on TSM74, a targeted protein degrader of XPO1. TSM74 employs a unique chemistry and mechanism of action to degrade proteins involved in cancer cell signaling, leading to rapid tumor regression and complete tumor removal in preclinical models. This approach aims to address cancers refractory to existing medicines while improving safety profiles compared to existing covalent inhibitors. By selectively targeting XPO1, Telo Therapeutics seeks to unlock the full potential of nuclear transport inhibition in oncology.
Target Audience
The primary target audience includes patients with cancers refractory to existing treatments, as well as oncologists and hematologists seeking safer and more effective therapeutic options.
Features
- Orally bioavailable nuclear transport inhibitors for systemic administration
- Selective targeting of XPO1 to degrade key cancer-driving proteins
- Unique chemistry and mechanism of action resulting in an improved safety profile
- Demonstrated rapid tumor regressions and complete tumor removal in preclinical cancer models
- Potential application across a range of solid and hematological cancers, including multiple myeloma and glioblastoma